Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
On Friday, BioAge Labs Inc. (NASDAQ:BIOA) announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag. STRIDES was being conducted in ...
Company will evaluate data from patients enrolled to date and share updated plans for azelaprag in Q1 2025 In parallel to evaluating azelaprag, Company will continue to advance earlier ...
KINSTON, N.C. (WITN) - The STRIDES Rockin’ Walk-A-Thon for diabetes awareness is coming to Kinston. The Kinston Host Lions Club is sponsoring the annual walk-a-thon on Saturday, March 29th, from 10 ...
RICHMOND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases ...
Sire: CAIRO PRINCE, gr/ro, 2011. Raced 2 yrs, 5 sts, 3 wins, $562,000. Won Holy Bull S (G2), Nashua S (G2); 2nd Remsen S (G2). Lifetime: 8 crops, 783 foals, 616 rnrs (79%), 440 wnrs (56%), 135 2yo ...
MUMBAI, Sept 2 (Reuters) - Strides Arcolab Ltd said on Tuesday it has got approval from the U.S. Food and Drug Administration for two more drugs, thereby taking the total approvals to 11. The drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results